GW Pharmaceuticals Investors Sue To Stop $7.2B Acquisition
Two shareholders in cannabinoid drugmaker GW Pharmaceuticals are suing to stop its planned $7.2 billion acquisition by another pharmaceutical company, saying the deal was the result of an unfair and misleading...To view the full article, register now.
Already a subscriber? Click here to view full article